• 1. An investigation of new infrared nonlinear optical material: BaCdSnSe4, and three new related centrosymmetric compounds: Ba2SnSe4, Mg2GeSe4, and Ba2Ge2S6?
  Kui Wu,Zhihua Yang,Shilie Pan Dalton Trans., 2015,44, 19856-19864
• 2. An arsenic trioxide nanoparticle prodrug (ATONP) potentiates a therapeutic effect on an aggressive hepatocellular carcinoma model via enhancement of intratumoral arsenic accumulation and disturbance of the tumor microenvironment?
  Xin Fu,Qing-rong Liang,Rong-guang Luo,Yan-shu Li,Xiao-ping Xiao,Lu-lu Yu,Wen-zhe Shan,Guang-qin Fan J. Mater. Chem. B, 2019,7, 3088-3099
• 3. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812
• 4. An automated computational approach to kinetic model discrimination and parameter estimation?
  Connor J. Taylor,Hikaru Seki,Friederike M. Dannheim,Mark J. Willis,Graeme Clemens,Brian A. Taylor,Thomas W. Chamberlain,Richard A. Bourne React. Chem. Eng., 2021,6, 1404-1411
• 5. An investigation into the origin of variations in photovoltaic performance using D–D–π–A and D–A–π–A triphenylimidazole dyes with a copper electrolyte?
  Govind Reddy Mol. Syst. Des. Eng., 2021,6, 779-789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Aminopyridines and derivatives

Research Brief on 2-Chloro-6-methoxypyridin-3-amine hydrochloride (CAS: 1216499-22-7): Recent Advances and Applications

2-Chloro-6-methoxypyridin-3-amine hydrochloride (CAS: 1216499-22-7) has emerged as a key intermediate in pharmaceutical synthesis, particularly in the development of kinase inhibitors and antimicrobial agents. Recent studies highlight its structural versatility as a pyridine derivative, where the chloro and methoxy substituents enable selective functionalization for drug discovery. A 2023 study in Journal of Medicinal Chemistry demonstrated its utility in constructing novel Bruton's tyrosine kinase (BTK) inhibitors, achieving 80% yield in a one-pot amination reaction under mild conditions.

New synthetic methodologies have been developed to optimize the production of this compound. Researchers at the University of Manchester (2024) reported a solvent-free mechanochemical synthesis route that reduces byproducts by 40% compared to traditional methods (Green Chemistry, DOI: 10.1039/D3GC04562H). The improved purity profile (≥99.5% by HPLC) makes it particularly valuable for GMP-grade applications in oncology drug candidates targeting PI3Kδ isoforms.

Biological evaluations reveal expanded therapeutic potential. When incorporated as a core scaffold in antimicrobial agents, derivatives showed potent activity against methicillin-resistant Staphylococcus aureus (MRSA) with MIC values of 2-4 μg/mL (Bioorganic & Medicinal Chemistry Letters, 2024). The hydrochloride salt form demonstrates enhanced water solubility (23 mg/mL at 25°C) critical for parenteral formulations, as evidenced in recent preclinical studies of antiviral compounds targeting RNA-dependent RNA polymerases.

Structural-activity relationship (SAR) studies utilizing 1216499-22-7 have identified optimal substitution patterns for CNS penetration. A 2024 patent application (WO2024/076521) discloses novel dopamine D3 receptor modulators using this intermediate, showing 10-fold selectivity over D2 receptors in PET imaging probes. Quantum mechanical calculations (DFT at B3LYP/6-311+G(d,p) level) confirm the electron-withdrawing effects of the chloro group significantly influence the compound's reactivity in palladium-catalyzed cross-couplings.

Current regulatory status updates indicate this intermediate has been included in the FDA's Drug Master File system (DMF #035612) as of Q1 2024, facilitating its use in clinical-stage compounds. Stability studies under ICH Q1A guidelines demonstrate satisfactory performance in accelerated conditions (40°C/75% RH for 6 months), supporting its adoption in commercial-scale manufacturing. Ongoing research explores its application in PROTAC degraders, where the aminopyridine moiety serves as an ideal linker attachment point.

The compound's safety profile has been further characterized through recent toxicological assessments. A 28-day repeat dose study in Sprague-Dawley rats established an NOAEL of 250 mg/kg/day, with particular attention to its hydrochloride salt form's effects on renal clearance pathways. These findings position 2-Chloro-6-methoxypyridin-3-amine hydrochloride as a versatile building block meeting both efficacy and safety requirements for next-generation therapeutics.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)